Trial results for the Phase 1b/2 study (NCT03901573) investigating atezolizumab in combination with NT-I7 for high-risk skin cancers were posted on ClinicalTrials.gov on 2025-10-22. The study, which enrolled 31 participants, was terminated.
Background
The study aimed to test whether the addition of NT-I7 to atezolizumab could provide clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma (MCC), and cutaneous Squamous Cell Carcinoma (cSCC).
Trial design
The study (NCT03901573) was a Phase 1b/2 trial that was terminated. It enrolled a total of 31 participants with high-risk melanoma, Merkel Cell Carcinoma, and cutaneous Squamous Cell Carcinoma. The trial investigated the combination of NT-I7 with atezolizumab. The primary objective of the Phase 1b part was to evaluate the safety and tolerability of this combination, including the estimation of the maximum tolerated dose and/or the recommended Phase 2 dose.
What this means
The termination of this Phase 1b/2 study means that no further data on the efficacy or detailed safety profile of atezolizumab in combination with NT-I7 for these high-risk skin cancers will be generated from this particular trial. The posted results primarily confirm participant counts for safety evaluation prior to termination, without providing specific safety outcomes or efficacy data.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT03901573, titled 'High-Risk Skin Cancers With Atezolizumab Plus NT-I7,' were posted on 2025-10-22 on clinicaltrials.gov.